12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Other News

Arena, Eisai endocrine/metabolic, neurology news

Last month, Eisai submitted a Citizen's Petition to FDA that said the agency erred by starting the five-year exclusivity period for obesity drug Belviq lorcaserin and epilepsy drug Fycompa perampanel before the pharma was able to begin "commercial marketing" of the drugs. FDA started the exclusivity periods on the dates the agency approved the drugs: June 27, 2012, for Belviq,...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >